Abstract
Background and Aims: Cardiac pathological hypertrophy is a risk factor that usually progresses to heart failure. Novel therapeutic strategies are needed to prevent or reverse pathological hypertrophy. Aim: To investigate the effects of mesenchymal stem cell (MSC)-derived EVs of different origin on cardiac hypertrophy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
